SCWorx Corp. (WORX) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001674227 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 14, 2026 | $706,049 | $-120,954 | $-1.35 | Filing |
| Mar 31, 2026 | May 15, 2026 | $744,899 | $-173,767 | $-0.16 | Filing |
| Dec 31, 2025 | Mar 31, 2026 | $768,899 | $-749,182 | $85.52 | Filing |
| Sep 30, 2025 | Nov 12, 2025 | $705,799 | $-1.3M | $-0.15 | Filing |
| Jun 30, 2025 | Aug 14, 2025 | $682,632 | $-1.9M | $-82.27 | Filing |
| Mar 31, 2025 | May 15, 2025 | $720,299 | $-476,303 | $-3.71 | Filing |
| Dec 31, 2024 | Mar 31, 2025 | $675,749 | $-195,290 | $-0.11 | Filing |
| Sep 30, 2024 | Nov 14, 2024 | $759,724 | $-424,963 | $-0.27 | Filing |
What would SCWorx Corp. have to report for its valuation to change?
At $1.38, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -73.1% a year, to $0.12. On that path the next quarter needs diluted EPS near $-0.04, against $-0.15 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -73.1% | -73.1% |
| EPS needed in final year | $0.12 | $0.12 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. WORX goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.